Hospitals Buy the Drug Cheap and Bill It at Full Price
A federal program requires manufacturers to sell outpatient drugs at deep discounts to hospitals serving low income populations. Nothing requires the hospital to pass the discount to the patient, and the spread has become a major revenue source.
A Discount With No Matching Obligation
The structure is unusual enough that it is worth stating plainly before anything else. Under the federal 340B drug pricing program, pharmaceutical manufacturers must sell covered outpatient drugs to eligible hospitals and clinics at a substantial statutory discount. Those entities then bill insurers and patients at ordinary rates. The difference is kept by the hospital.
There is no requirement that the discount be passed to the patient receiving the drug, and no requirement that the retained spread be spent on any specific activity. The statute expresses an intent that covered entities stretch scarce federal resources to reach more patients, and that language has never been converted into an enforceable spending rule.
Why Manufacturers Participate
Participation is not voluntary in any meaningful sense. A manufacturer that declines to offer 340B pricing cannot have its drugs covered by Medicaid or Medicare Part B, which for most products is commercially fatal. So the discount functions as a condition of access to the largest payers in the country.
The discount is calculated from a formula tied to Medicaid rebate mechanics, and for some products it is very large. Combined with billing at commercial reimbursement rates, the resulting margin per unit can exceed anything in ordinary hospital operations.
| Step | Amount |
|---|---|
| Manufacturer list price | High |
| Price paid by covered entity | Deeply discounted |
| Amount billed to commercial insurer | Full negotiated rate |
| Retained by the hospital | The spread |
How a Modest Program Became a Large One
Two expansions drove the growth. The first was eligibility: the categories of qualifying entity broadened over time to include critical access hospitals, rural referral centers, and others, substantially increasing the number of participants.
The second, and more consequential, was the contract pharmacy arrangement. Covered entities were permitted to dispense 340B drugs through outside retail pharmacies acting under contract, rather than only through their own in house pharmacies. That change decoupled the program from the physical safety net site, allowing a qualifying hospital to capture 340B margin on prescriptions filled at chain pharmacies across a wide area.
The result is that program purchases grew from a modest figure into the tens of billions of dollars annually, making it one of the largest drug pricing arrangements in the country by volume.
The design assumed the hospital serving poor patients and the site dispensing the drug were the same place. Contract pharmacy severed that link, and almost every subsequent dispute traces back to it.
The Argument From Hospitals
The hospital case is substantive. Safety net institutions treat large numbers of uninsured and underinsured patients at a loss, operate emergency departments that cannot turn anyone away, and receive inadequate reimbursement from public payers. 340B margin cross subsidizes services that lose money, including charity care, community clinics, behavioral health, and outreach programs that no payer funds directly.
Remove it, hospitals argue, and those services close. Since the alternative funding mechanism does not exist, an imperfect subsidy is better than none.
The Argument From Manufacturers and Critics
The counterargument is equally direct. The program has grown far beyond its original scale without a corresponding expansion in documented charity care. Studies have found weak correlation between the size of a hospital 340B margin and the amount of uncompensated care it provides, and have noted growth in contract pharmacy relationships in affluent areas rather than underserved ones.
Critics also argue that the spread creates an incentive to prescribe higher priced drugs, since the margin scales with the list price, and that acquisitions of physician practices by 340B hospitals are partly motivated by extending program eligibility to those sites.
The Escalation
Beginning around 2020, manufacturers began unilaterally restricting contract pharmacy shipments, arguing the statute never authorized them. Litigation followed in multiple circuits, with mixed outcomes and no uniform national rule. Several states enacted laws requiring manufacturers to honor contract pharmacy arrangements, which produced a further layer of conflict between state mandates and federal statutory interpretation.
Meanwhile some manufacturers have proposed moving from an upfront discount to a rebate model, under which the covered entity pays full price and claims the discount afterward with documentation. Hospitals object that this shifts working capital burden onto them and functions as a mechanism to deny claims. The dispute over rebate models is the current front line.
What It Means Commercially
For pharmaceutical manufacturers, 340B is a material and growing gross to net deduction, meaning the gap between list price and realized revenue, and it is worth tracking as a share of revenue rather than as a footnote. For hospital systems, 340B margin can represent a significant share of operating income, which makes any adverse legal or regulatory development a direct earnings risk. For anyone reading either sector, the useful step is to find the disclosure quantifying the program impact, because it is frequently large and rarely highlighted.
The Bottom Line
The 340B program subsidizes safety net providers by requiring a private industry to sell at a discount and permitting the recipient to bill at full price, with no obligation attached to the difference. Both sides of the argument contain truth: the hospitals genuinely need cross subsidy that no other mechanism supplies, and the program genuinely operates far beyond the footprint it was designed for. The unresolved question is not whether safety net care should be funded. It is whether an unmonitored spread on drug purchases is a sensible way to fund it.